Vitamin E (α-
tocopherol) plays a key role in the regulation of cell growth and differentiation and has been studied as a potential chemopreventive agent for
prostate cancer. The association of serum
vitamin E concentrations with
cancer risk may be modified by genetic variations in
vitamin E-related genes. We examined whether variants in
vitamin E-related genes were associated with risk of
prostate cancer in a nested case-control study using 483
prostate cancer cases and 542 matched controls of European ancestry from a large U.S. multicenter trial that had available measurements of serum
vitamin E concentrations and genotyping of 3 genome-wide association study meta-analysis-identified single-nucleotide polymorphisms (SNPs) associated with circulating
vitamin E.
ORs and 95% CIs were calculated using unconditional logistic regression adjusted for age, family history of
prostate cancer, and serum total
cholesterol. Findings suggest lower
prostate cancer risk for men whose genotypes reflect higher
vitamin E (i.e., α-
tocopherol) status. An SNP (rs964184) near budding-site selection
protein 13 (yeast) (BUD13), zinc finger
protein 259 (ZNF259), and
apolipoprotein A5 (APOA5) on 11q23.3 was significantly associated with
prostate cancer risk (per-allele OR = 0.75; 95% CI: 0.58, 0.98; P-trend = 0.03). The association between rs964184 and
prostate cancer risk was stronger among homozygous carriers of the minor allele (OR = 0.27; 95% CI: 0.09, 0.83). Another variant, rs11057830 in
scavenger receptor class-B member 1 (SCARB1) on 12p24.31, approached statistical significance (OR = 0.32; 95% CI: 0.10, 1.01, P = 0.05; 2 minor allele copies). This study suggests that polymorphisms near BUD13/ZNF259/APOA5, involved in
vitamin E transport and metabolism, may be associated with lower risk of
prostate cancer. This trial was registered at clinicaltrials.gov as NCT00002540.